A Case of Pembrolizumab And Lenvatinib As An Alterntive Therapy For Leiomyosarcoma

Gynecologic Oncology Reports（2023）

引用 0|浏览1

暂无评分

摘要

•Research surrounding treatment of leiomyosarcoma (LMS) treatment remains sparse.•Pembrolizumab/lenvatinib has been reported as a therapy for endometrial cancer, though not yet as therapy for LMS.•This report demonstrates disease regression after use of pembrolizumab and lenvatinib in a patient with recurrent LMS.

查看译文

关键词

Uterine sarcoma,Therapy,Prevention

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要